Axial Cell Systems develops gene therapies targeting the underlying causes of sporadic ALS by identifying and leveraging the unique properties of resilient neurons. Their approach aims to make vulnerable neurons more resistant to the disease, offering a novel treatment strategy for ALS.
Funding
Funding not disclosed
Founders
Product
Problem
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options that primarily address symptoms rather than the underlying causes. Current therapies do not target the specific mechanisms that make motor neurons vulnerable to degeneration in sporadic ALS. This results in a lack of effective treatments to slow or halt disease progression.
Solution
Axial Cell Systems is developing gene therapies designed to enhance the resilience of motor neurons affected by sporadic ALS. Their approach focuses on identifying and leveraging the intrinsic properties of neurons that exhibit resistance to the disease. By understanding these protective mechanisms, Axial Cell Systems aims to develop targeted gene therapies that can make vulnerable neurons more resistant to the pathological processes that drive ALS progression. This strategy offers a novel approach to treating ALS by directly addressing the underlying cellular vulnerabilities that contribute to the disease.
Target Audience
The primary target audience includes individuals diagnosed with sporadic ALS and their healthcare providers, as well as pharmaceutical companies interested in novel neurodegenerative disease treatments.
Features
- Gene therapy approach targeting specific vulnerabilities of motor neurons in sporadic ALS.
- Identification and utilization of protective mechanisms found in resilient neurons.
- Development of therapies to enhance neuronal resistance to disease-related stress.